Fig 1: TIM-3 IHC detection on ccRCC tumors. 10 random tumor regions evenly spread on the slides were selected for analyzes. A custom phenotyping algorithm was used for quantification of total PAX8 + Cytokeratin + tumor cells and manual counting was performed for quantification of TIM3 + tumor cells. A Absorption view (× 20) of a ccRCC primary tumor FFPE sample analyzed with multiplex IHC. Blue: DAPI; Yellow: PanCytokeratine-PAX; Red: TIM-3. Arrows: TIM-3 positive tumor cells; Arrowhead: TIM-3 positive non-tumor cell. B % of TIM-3-positive tumor cells among tumor cells in each sample (n = 22). C Association of plasma sTIM-3 with TIM-3 tumor status
Fig 2: Flow cytometry quantification of TIM-3-positive (TIM3 +) cells in PBMC of ccRCC patients (Colcheckpoint cohort, n = 27). A Gating strategy; we considered CD3-SSC-Ahigh cells as myeloid cells, CD3 + SSC-Alow as T cells and CD3-SSC-Alow as non-T lymphoid cells. B Percentage of TIM3 + cells within PBMC of Colcheckpoint participants. C Proportion of CD3- myeloid, CD3- lymphoid and CD3 + lymphoid cells within TIM3 + cells in PBMC of Colcheckpoint participants
Fig 3: Obradovic et al. ccRCC scRNAseq dataset. A Tumor and adjacent tissue samples. Upper section: UMAP of cell lineages; middle section: HAVCR2 expression; lower section: HAVCR2 + ADAM + double-positive cells repartition. B % of cells in the pooled dataset expressing HAVCR2 and ADAM10 and/or ADAM17 in broad lineages. HAVCR2 + ADAM10 +—detection of ADAM10 transcripts but not ADAM17; HAVCR2 + ADAM17 +—detection of ADAM17 transcripts but not ADAM10, HAVCR2 + ADAM10 + 17 +—detection of both metalloproteinases. C Comparison of the proportions of HAVCR2 + ADAM + cells within the lymphoid and myeloid lineages, for each patient in tumor samples
Supplier Page from Abcam for Mouse TIM-3 ELISA Kit